ImmunityBio Inc.

Company IBRX

Last mentioned: Mar 25, 2026

Timeline

  1. Expected Regional Launch

    Anticipated availability of ANKTIVA in Macau oncology centers.

  2. Macau SAR Approval

    Macau Health Bureau grants regulatory clearance for ANKTIVA.

  3. U.S. Commercial Launch

    ImmunityBio begins commercial distribution of ANKTIVA in the U.S.

  4. U.S. FDA Approval

    ANKTIVA receives first-ever approval for NMIBC in the United States.

Stories mentioning ImmunityBio Inc. 1

regulation Bullish

ImmunityBio Secures Macau Approval for ANKTIVA, Eyeing Chinese Oncology Market

ImmunityBio Inc. has received regulatory approval for its flagship immunotherapy, ANKTIVA, in the Macau Special Administrative Region of China. This milestone marks the first international expansion for the IL-15 superagonist following its 2024 U.S. FDA approval, positioning the company to tap into the significant oncology market in the Greater Bay Area.

2 sources